755 Results of a phase I trial of FT500, a first-in-class, off-the-shelf, iPSC–derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.